Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Heron Therapeutics clinical trials
Also known as A.P. Pharma, AP Pharma.
The registry lists 26 studies whose lead sponsor is Heron Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 17, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Heron Therapeutics.
- Heron Therapeutics26 studiesSame company
Something wrong?
Focus areas
Conditions Heron Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 26 of 26.
- HTX-011 for Post-bunionectomy AnalgesiaCompletedNCT02471898Phase 2
- Dose-Escalation Study of HTX-034 Following BunionectomyCompletedNCT04398329Phase 1/2
- Study of Post-Herniorrhaphy Non-opioid MMA RegimensCompletedNCT03907176Phase 3
- Pediatric Postoperative Analgesia Herniorrhaphy StudyWithdrawnNCT03922048Phase 2
- Pilot Herniorrhaphy Study for Postoperative AnalgesiaCompletedNCT02504580Phase 2
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for CancerCompletedNCT00343460Phase 3
- A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HECCompletedNCT02106494Phase 3
- Phase 2 Herniorrhaphy Study for Opioid EliminationCompletedNCT03695367Phase 2
- Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty SurgeryCompletedNCT02689258Phase 2
- Phase 2 Bunionectomy HTX-011 Administration StudyCompletedNCT03718039Phase 2
- Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)CompletedNCT03237481Phase 3
- Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)TerminatedNCT04470622Phase 2
- Bunionectomy Study for Postoperative Analgesia (EPOCH 1)CompletedNCT03295721Phase 3
- Total Knee Arthroplasty Infiltration Study for Postoperative AnalgesiaCompletedNCT03015532Phase 2
- Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) RegimenCompletedNCT03974932Phase 3
- Phase 2B Upper Extremity Nerve Block StudyCompletedNCT03011333Phase 2
- Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following BunionectomyCompletedNCT02762929Phase 2
- A Phase I Study of the Effects of APF530 Exposure, Granisetron and MoxifloxacinCompletedNCT01416259
- A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.CompletedNCT06109415Phase 4
- A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZECompletedNCT06109428Phase 4
- A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.Active, not recruitingNCT05109312Phase 4
- Safety Study of Repeat Doses of SUSTOL in AdultsActive, not recruitingNCT05434663Phase 4
- HTX-011 in Spinal SurgeryCompletedNCT04911062Phase 2
- HTX-011 Administration Study in Planned Caesarean Section ProcedureCompletedNCT03955211Phase 2
- Extended Delivery of Bupivacaine Study in HerniorrhaphyCompletedNCT04102267Phase 4
- Bupivacaine HCl PK and Safety in Augmentation MammoplastyCompletedNCT03705065Phase 4